美国青少年和成人用破伤风-白喉-五组分无细胞百日咳联合疫苗加强免疫后10年体液免疫持久性研究
在一项前瞻性随机关键III期临床试验中,研究了破伤风-白喉-无细胞百日咳疫苗(Tdap)和破伤风-白喉疫苗(Td)在11-64岁参与者中的免疫原性和反应原性。本文报告接种后10年的抗体持久性。结果显示Tdap和Td提供针对白喉和破伤风的持久保护性免疫应答,但百日咳抗体 Substantial waning。
要点
- Tdap和Td接种后10年,白喉抗体≥0.1 IU/mL在青少年中保持≥95%,在成人中保持≥80%。
- 几乎所有参与者研究期间破伤风抗体≥0.1 IU/mL。
- PT抗体在接种后约5年降至接种前水平;FHA、PRN和FIM抗体在5年和10年下降但仍高于接种前数倍。
核心结论
- Tdap和Td提供针对白喉和破伤风的持久保护性免疫应答;Tdap后百日咳抗体通常超过接种前水平但显著下降;这些数据可为成人重复接种Tdap的必要性讨论提供信息。
研究设计与样本
- 前瞻性、随机关键III期临床试验的10年血清学随访;原试验纳入11-64岁参与者,接种Tdap或Td,并采集接种前和接种后血清;在接种后1、3、5和10年招募参与者捐献血清。
主要发现
- 初始纳入1457名Tdap受种者和1152名Td受种者;最终研究采血点时Tdap组有175人可用。
- 接种后1个月,两组几乎所有青少年白喉抗体水平≥0.1 IU/mL,5年和10年时≥95%疫苗接种者维持该水平。
- 成人中,接种后1个月≥94%白喉抗体水平≥0.1 IU/mL,5年和10年时≥80%维持该水平。
- 几乎所有参与者整个研究期间破伤风抗体≥0.1 IU/mL。
- PT抗体在接种后约5年降至接种前水平;FHA、PRN和FIM抗体在5年和10年下降但仍高于接种前水平数倍。
关键数值与推荐
- 白喉抗体水平≥0.1 IU/mL:青少年接种后1个月近全部,5年和10年≥95%;成人接种后1个月≥94%,5年和10年≥80%。
- 破伤风抗体水平≥0.1 IU/mL:几乎所有参与者整个研究期间维持。
- PT抗体:约5年降至接种前水平;FHA、PRN和FIM抗体:5年和10年下降但仍高于接种前数倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a prospective, randomized pivotal phase III clinical trial, the immunogenicity and reactogenicity of a tetanus-diphtheria-acellular pertussis vaccine (Tdap) and a tetanus-diphtheria vaccine (Td) vaccine were studied in participants aged 11-64 years. Here we report antibody persistence through 10 years after vaccination. METHODS: Participants who received Tdap or Td in the original phase III trial and provided pre- and post-vaccination serum samples were recruited to donate sera at 1, 3, 5 and 10 years post-vaccination. Antibody concentrations were measured using standard assay techniques. RESULTS: Initially, 1457 Tdap and 1152 Td recipients were included; of these, 175 persons from Tdap group were available at the final study bleed point. Nearly all adolescents in both groups had diphtheria antibody levels ≥0.1 IU/mL 1 month after vaccination, which were maintained in ≥95% of vaccinees at 5 and 10 years. Among adults, ≥94% had diphtheria antibody levels ≥0.1 IU/mL 1 month after vaccination, which were maintained in ≥80% at 5 and 10 years. Nearly all participants had tetanus antibodies ≥0.1 IU/mL throughout the study. PT antibodies declined to pre-vaccination levels approximately 5 years post-vaccination; FHA, PRN and FIM antibodies waned at 5 and 10 years but remained several-fold higher than pre-vaccination levels. CONCLUSIONS: Tdap and Td provide long-lasting protective immune responses against diphtheria and tetanus. Pertussis antibodies following Tdap generally exceeded pre-vaccination levels throughout the study, but showed substantial waning. These data may inform discussion of the need for repeat Tdap booster vaccinations among adults. TRIAL REGISTRATION: The original phase III clinical trial, as well as the 1-, 3-, and 5-year serology follow-up studies were conducted prior to mandatory registration. The 10-year serology follow-up data collection was performed as part of a repeat Tdap administration clinical trial that was registered under clinicaltrials.gov number NCT01439165.
引用
- Pool V, Tomovici A, Johnson DR, et al. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. Vaccine. 2018. PMID: 29573876. doi:10.1016/j.vaccine.2018.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。